Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Lancet Commission

    - PMLiVE

    Lilly and WHO Foundation partner to support global dementia action plan

    The partnership will provide financial support and strengthen early detection and intervention efforts

    - PMLiVE

    Lilly launches global Alzheimer’s campaign with Julianne Moore

    The new ‘Brain Health Matters’ campaign urges the public to prioritise brain health

    - PMLiVE

    GSK to explore link between Shingrix and dementia risk in new UK research collaboration

    More than 55 million people worldwide are currently living with the neurodegenerative disease

    - PMLiVE

    UK drug repurposing study identifies several potential dementia treatments

    An estimated 982,000 people in the UK are currently living with the neurodegenerative disease

    - PMLiVE

    Eli Lilly shares positive results for modified titration of Alzheimer’s drug donanemab

    The neurodegenerative disorder accounts for up to 75% of the 982,000 dementia cases in the UK

    - PMLiVE

    Astellas and AviadoBio enter exclusive dementia gene therapy deal worth over $2bn

    Frontotemporal dementia accounts for less than one in 30 cases of the neurodegenerative disorder

    - PMLiVE

    Lancet Commission report identifies two new modifiable dementia risk factors

    The new risk factors identified are untreated vision loss and high low-density lipoprotein

    - PMLiVE

    Study reveals GSK’s new recombinant shingles vaccine could reduce dementia risk

    Shingrix reduced dementia diagnoses by 17% compared to Merck & Co’s Zostavax after six years

    - PMLiVE

    NHS figures reveal record number of people in England being diagnosed with dementia

    Around a third of people living with dementia in England have not received a diagnosis

    - PMLiVE

    AI tool better predicts progress of Alzheimer’s versus current clinical tests

    The most common form of dementia accounts for up to 80% of all cases

    - PMLiVE

    Researchers develop AI blood test to predict Parkinson’s seven years before symptom onset

    The neurodegenerative condition currently affects nearly ten million people worldwide

    - PMLiVE

    Eli Lilly’s Alzheimer’s drug unanimously endorsed by FDA panel of experts

    The company is seeking approval of donanemab to treat patients with early stages of the disease

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links